Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDSC and AD-MSC in FSHD
NCT02208713Phase 1Unknown
- Sponsor
- Royan Institute
- Start
- May 2014
- Primary completion
- Nov 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of adipose derived mesenchymal stromal cells in facioscapulohumeral muscular dystrophy (FSHD), sponsored by Royan Institute. Primary endpoints: Myalgia at 1 month and Mass formation at 6 months. Status: unknown.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02208713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02208713.